Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors

Key facts

Sponsor

University Health Network, Toronto

Principal Investigator

Lillian Siu, MD

Princess Margaret Cancer Centre

Enrollment

13 enrolled

Eligibility

18 years · All sexes

Timeline

2013 – 2021

Study locations (1)

• Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Collaborators

Princess Margaret Hospital, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuroendocrine neoplasm of pancreas

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06246630
  In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor
  Ruijin Hospital
• RECRUITINGNANCT05243082
  Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms
  Oslo University Hospital

See all trials for Neuroendocrine neoplasm of pancreas →